Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials - PubMed
7 days ago
- #BGF
- #clinical-trial
- #asthma
- Budesonide-glycopyrronium-formoterol fumarate dihydrate (BGF) was evaluated for uncontrolled asthma in two phase 3 trials (KALOS and LOGOS).
- BGF showed improved lung function (FEV1 AUC0-3 and trough FEV1) compared to budesonide-formoterol fumarate dihydrate (BFFA/BFFS).
- BGF 28.8 μg reduced severe exacerbation rates versus BFFcombined (incidence rate ratio 0.86, p=0.012).
- Adverse events were similar across treatment groups, with no treatment-related deaths reported.
- BGF benefits patients with inadequately controlled asthma, regardless of recent exacerbation history.
- The studies were funded by AstraZeneca, with several authors being employees or having financial ties to the company.